Anavex Life Sciences Corp. and Partex N.V. Group announced a strategic partnership with the overall ambition to reshape the future of the biopharma business model.
By combining Anavex's innovative small molecule precision medicine drug development platform and Partex's disruptive approach of Artificial Intelligence (AI) enabled drug development and healthcare sales marketing, this collaboration is intended to drive efficiency, effectiveness, and innovation across the value chain with patient-centric focus at every step.
Under the partnership, Anavex and Partex intend to co-develop a disease-focused Patient App ecosystem. The first feature will be to inform patients and caregivers on preventive and curative options available in clinics and on the market. Further, Partex will implement AI-based ‘Healthcare Sales Marketing’ in preparation for Anavex’s late stage drug pipeline.
Gunjan Bhardwaj, PhD, CEO of Partex, commented: “We are excited to embark on this impactful journey together with Anavex. We will start by extending our patient ecosystem together. Further, we intend to leverage our Life Sciences Language Processing platform with Generative Artificial Intelligence capabilities, which is expected to significantly improve patient outcomes.”
"As a biopharmaceutical Company with a proprietary late stage pipeline for CNS indications, Anavex brings expertise in precision medicine drug development to the partnership and we are excited to collaborate with Partex and fully leverage AI to expand beyond our R&D into healthcare sales marketing to bring better treatment options to patients in a patient centric way,” said, Christopher U Missling, PhD, President and Chief Executive Officer of Anavex.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!